Skip to main content

Technology

By Jessica Hagen | 05:22 pm | January 22, 2026
Carlsmed's cofounder, president and CEO sat down with MobiHealthNews outside the JPM Healthcare Conference to discuss how the company uses patient imaging and 3D printing to create personalized spine implants for surgery.
By Jessica Hagen | 12:05 pm | January 22, 2026
AION Labs CEO sat down with MobiHealthNews outside the JPM Healthcare Conference to discuss the acquisition he says represents a milestone for Israel’s biotech ecosystem.
By Jessica Hagen | 03:41 pm | January 21, 2026
Ahead of HIMSS26, Mayo Clinic’s Ugur Sener and Taylor Galloway preview their talk on using digital tools and decentralized trials to deliver brain cancer care remotely.
By Jessica Hagen | 02:04 pm | January 21, 2026
The investment brings the company's total raise to nearly $700 million.
By Jessica Hagen | 11:53 am | January 21, 2026
The $50 million Horizon 1000 pilot initiative will support countries in Africa, beginning in Rwanda, as they work to apply AI technology in their healthcare systems.
By Jessica Hagen | 12:13 pm | January 20, 2026
The CEO of Transcarent sat down with MobiHealthNews outside the JPM Healthcare Conference to discuss the state of digital health and how his company is working to improve access to care.
By Jessica Hagen | 11:35 am | January 20, 2026
New CEO of Dexcom, Jake Leach, joined MobiHealthNews at the JPM Healthcare Conference to discuss his leadership priorities, CGM access and the role of wearables in preventive care.
By Andrea Fox | 05:38 pm | January 16, 2026
Amy Tucker of Advocate Health's Sanger Heart & Vascular Institute explains what it takes to move to a scalable platform that improves clinical administration and patient care.
By Jessica Hagen | 12:59 pm | January 16, 2026
Outside the JPM Healthcare Conference, Thomas Clozel, cofounder and CEO of Owkin, sat down with MobiHealthNews to discuss how the company is using AI to find causality in disease.
By HIMSS TV | 10:43 am | January 16, 2026
Michael Abrams of Numerof and Associates says that oversight for AI used in mental health care should mirror that of pharmaceuticals, with clear standards, safety testing and ongoing monitoring.